AGTC - アプライド・ジェネティック・テクノロジ―ズ (Applied Genetic Technologies Corporation) アプライド・ジェネティック・テクノロジ―ズ

 AGTCのチャート


 AGTCの企業情報

symbol AGTC
会社名 Applied Genetic Technologies Corp (アプライド・ジェネティック・テクノロジ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31 2016 its product candidates included treatments for X-linked retinoschisis (XLRS) over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31 2016 the Company was engaged in developing three discovery programs targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss extreme light sensitivity resulting in daytime blindness and reduced or complete loss of color discrimination achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).   アプライド・ジェネティック・テクノロジ―ズは、米国のバイオ医薬品企業。臨床段階で、眼科と肺疾患のための遺伝子治療医薬品の開発に従事する。主要な開発段階の医薬品は、X連鎖網膜分離症(XLRS)、色覚異常(ACHM)、およびX連鎖網膜色素変性症(XLRP)の治療向けを含む。本社はフロリダ州。  Applied Genetic Technologies Corp. (AGTC) is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC's most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company's industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, an innovator in the emerging field of optogenetics and retinal coding.
本社所在地 14193 N.W. 119th Terrace Suite 10 Alachua FL 32615 USA
代表者氏名 Scott Koenig スコットケーニッヒ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 386-462-2204
設立年月日 36161
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数
url www.agtc.com
nasdaq_url https://www.nasdaq.com/symbol/agtc
adr_tso
EBITDA EBITDA(百万ドル) -21.20900
終値(lastsale) 6.55
時価総額(marketcap) 118745919.4
時価総額 時価総額(百万ドル) 115.30140
売上高 売上高(百万ドル) 24.18600
企業価値(EV) 企業価値(EV)(百万ドル) 10.39640
当期純利益 当期純利益(百万ドル) -22.09100
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Applied Genetic Technologies Corp revenues decreased 39% to $24.2M. Net loss before extraordinary items totaled $22.1M vs. income of $407K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Other expense increase from $47K to $125K (expense).

 AGTCのテクニカル分析


 AGTCのニュース

   AGTC to Present at the H.C. Wainwright Global Investment Conference  2022/05/18 12:00:00 GlobeNewswire
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that Sue Washer, President & Chief Executive Officer, Jon Lieber, Chief Financial Officer, and Susan Schneider, Chief Medical Officer, will be presenting virtually at the H.C. Wainwright Global Investment Conference held May 23 - 26, 2022.
   The Daily Biotech Pulse: Pfizer-BioNTech''s COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio''s AP-013 Trial Under Independent Investigation  2022/05/17 13:04:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA May Authorize Pfizer-BioNTech''s COVID-19 Booster For 5-11 Year Kids Soon: NYT The FDA is expected to authorize a booster shot of Pfizer Inc (NYSE: PFE )/ BioNTech SE''s (NASDAQ: BNTX ) COVID-19 vaccine for children ages 5 to 11, likely Tuesday, the New York Times reported , citing people familiar with the matter. It is unclear how much demand there is for the third dose in the age group. According to the U.S. Centers for Disease Control and Prevention, just 28.8% of children ages 5 to 11 are fully vaccinated. Applied Genetic''s Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months Applied Genetic Technologies Corporation (NASDAQ: AGTC ) reported three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501 for X-linked retinitis pigmentosa, an inherited condition causing progressive vision loss in boys and young men. AGTC-501 is a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene.
   Applied Genetic''s Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months  2022/05/17 10:39:43 Benzinga
Applied Genetic Technologies Corp (NASDAQ: AGTC ) reported three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501 for X-linked retinitis pigmentosa (XLRP), an inherited condition causing progressive vision loss in boys and young men. AGTC-501 is a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene. There were robust improvements in visual sensitivity, the trial''s primary efficacy endpoint, in multiple … Full story available on Benzinga.com
   A Quick Glance At Applied Genetic Technologies Corporation (NASDAQ: AGTC) Stock: It Is up 20.55% From Its 52-Week Low; YTD, It Is Down -61.63 Percent  2022/05/14 20:00:00 Marketing Sentinel
During the last session, Applied Genetic Technologies Corporation (NASDAQ:AGTC)’s traded shares were 0.33 million, with the beta value of the company hitting 1.66. At the end of the trading day, the stock’s price was $0.73, reflecting an intraday gain of 15.62% or $0.1. The 52-week high for the AGTC share is $4.65, that puts it … A Quick Glance At Applied Genetic Technologies Corporation (NASDAQ: AGTC) Stock: It Is up 20.55% From Its 52-Week Low; YTD, It Is Down -61.63 Percent Read More »
   Applied Genetic Technologies Corporation (NASDAQ:AGTC) Shares Plunged -11.73% In A Week – But Can It Maintain Its Gains?  2022/04/30 14:00:00 Marketing Sentinel
In last trading session, Applied Genetic Technologies Corporation (NASDAQ:AGTC) saw 0.35 million shares changing hands with its beta currently measuring 1.65. Company’s recent per share price level of $0.90 trading at -$0.04 or -4.16% at ring of the bell on the day assigns it a market valuation of $47.67M. That closing price of AGTC’s stock … Applied Genetic Technologies Corporation (NASDAQ:AGTC) Shares Plunged -11.73% In A Week – But Can It Maintain Its Gains? Read More »
   Applied Genetic Technologies (NASDAQ:AGTC) Upgraded at Zacks Investment Research  2021/12/10 21:48:42 Dakota Financial News
Applied Genetic Technologies (NASDAQ:AGTC) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates []
   Brokerages Anticipate Applied Genetic Technologies Co. (NASDAQ:AGTC) to Post -$0.37 EPS  2021/12/05 20:44:41 Transcript Daily
Equities research analysts expect that Applied Genetic Technologies Co. (NASDAQ:AGTC) will post earnings per share of ($0.37) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Applied Genetic Technologies earnings, with the highest EPS estimate coming in at ($0.31) and the lowest estimate coming in at ($0.42). Applied Genetic Technologies []
   Should Applied Genetic Technologies Corporation (NASDAQ: AGTC) Revive After A -296.31% Drop From Highs?  2021/11/25 18:00:00 Marketing Sentinel
During the last session, Applied Genetic Technologies Corporation (NASDAQ:AGTC)s traded shares were 0.38 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stocks price was $2.44, reflecting an intraday gain of 2.09% or $0.05. The 52-week high for the AGTC share is $9.67, that puts it Should Applied Genetic Technologies Corporation (NASDAQ: AGTC) Revive After A -296.31% Drop From Highs? Read More »
   AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer  2021/11/16 13:00:00 Intrado Digital Media
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment of Abraham Scaria, Ph.D., as Chief Science Officer.
   FY2022 EPS Estimates for Applied Genetic Technologies Co. Decreased by Cantor Fitzgerald (NASDAQ:AGTC)  2021/11/15 08:32:41 Dakota Financial News
Applied Genetic Technologies Co. (NASDAQ:AGTC) Equities research analysts at Cantor Fitzgerald decreased their FY2022 EPS estimates for Applied Genetic Technologies in a research note issued on Wednesday, November 10th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings per share of ($1.61) for the year, down from their prior []
   Applied Genetic Technologies Corp Shares Near 52-Week Low - Market Mover  2021/07/16 00:34:18 Kwhen Finance
Applied Genetic Technologies Corp (AGTC) shares closed today at 1.7% above its 52 week low of $3.53, giving the company a market cap of $153M. The stock is currently down 12.2% year-to-date, down 36.2% over the past 12 months, and down 76.3% over the past five years. This week, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 rose 0.4%. Trading Activity Trading volume this week was 34.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1471.3% The company's stock price performance over the past 12 months lags the peer average by -109.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk  2021/07/15 02:47:09 Seeking Alpha
   Applied Genetic Technologies Corp Shares Close in on 52-Week Low - Market Mover  2021/07/15 00:11:01 Kwhen Finance
Applied Genetic Technologies Corp (AGTC) shares closed today at 1.7% above its 52 week low of $3.53, giving the company a market cap of $159M. The stock is currently down 8.6% year-to-date, down 33.6% over the past 12 months, and down 75.9% over the past five years. This week, the Dow Jones Industrial Average rose 0.9%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 73.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -847.7% The company's stock price performance over the past 12 months lags the peer average by -107.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Huge Demand of Next Generation Contact Lenses and Visual Prostheses Market by 2026 | Abbott, Allergan, Bionic Sight, Alden Optical, Applied Genetic Technologies  2021/07/13 13:52:25 Tramways Monthly
Get Sample Report Buy Complete Report Request for Customization Global Next Generation Contact Lenses and Visual Prostheses Market has significant drivers and future opportunities for vendors, the study includes in-depth assessment of competitive environment, product market size, product benchmarking, market dynamics, product innovations, financial analysis, strategic analysis, etc. Apart from this, the report examines []
   Volume Actives: Electrameccanica Vehicles Corp. (NASDAQ:SOLO), Applied Genetic Technologies Corporation (NASDAQ:AGTC)  2021/07/07 22:05:45 Stock Equity
Electrameccanica Vehicles Corp. (NASDAQ:SOLO) with the stream of -3.20% also noticed, India Applied Genetic Technologies Corporation (NASDAQ:AGTC) encountered a rapid change of -1.30% in the last hour of Wednesdays trading The post Volume Actives: Electrameccanica Vehicles Corp. (NASDAQ:SOLO), Applied Genetic Technologies Corporation (NASDAQ:AGTC) appeared first on Stocks Equity .

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アプライド・ジェネティック・テクノロジ―ズ AGTC Applied Genetic Technologies Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)